1
|
The Interplay of Sirtuin-1, LDL-Cholesterol, and HDL Function: A Randomized Controlled Trial Comparing the Effects of Energy Restriction and Atorvastatin on Women with Premature Coronary Artery Disease. Antioxidants (Basel) 2022; 11:antiox11122363. [PMID: 36552571 PMCID: PMC9774144 DOI: 10.3390/antiox11122363] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2022] [Revised: 11/16/2022] [Accepted: 11/24/2022] [Indexed: 12/05/2022] Open
Abstract
INTRODUCTION HDL function has gained prominence in the literature as there is a greater predictive capacity for risk in early coronary artery disease when compared to the traditional parameters. However, it is unclear how dietary energy restriction and atorvastatin influence HDL function. METHODS A randomized controlled trial with 39 women with early CAD divided into three groups (n = 13): energy restriction (30% of VET), atorvastatin (80 mg), and control. Analyses of traditional biochemical markers (lipid and glucose profile), circulating Sirt-1, and HDL function (lipid composition, lipid transfer, and antioxidant capacity). RESULTS Participants' mean age was 50.5 ± 3.8 years. Energy restriction increased Sirt-1 by 63.6 pg/mL (95%CI: 1.5-125.7; p = 0.045) and reduced BMI by 0.8 kg/m2 (95%CI: -1.349--0.273; p = 0.004) in a manner independent of other cardiometabolic factors. Atorvastatin reduced LDL-c by 40.0 mg/dL (95%CI: -69.910--10.1; p = 0.010). Increased Sirt-1 and reduced BMI were independently associated with reduced phospholipid composition of HDL (respectively, β = -0.071; CI95%:-0.136--0.006; p = 0.033; β = 7.486; CI95%:0.350-14.622; p = 0.040). Reduction in BMI was associated with lower HDL-free cholesterol (β = 0.818; CI95%:0.044-1.593; p = 0.039). LDL-c reduction by statins was associated with reduced maximal lipid peroxide production rate of HDL (β = 0.002; CI95%:0.000-0.003; p = 0.022) and total conjugated diene generation (β = 0.001; CI95%:0.000-0.001; p = 0.029). CONCLUSION This study showed that energy restriction and atorvastatin administration were associated with changes in lipid profile, serum Sirt-1 concentrations, and HDL function.
Collapse
|
2
|
He M, Wang J, Liang Q, Li M, Guo H, Wang Y, Deji C, Sui J, Wang YW, Liu Y, Zheng Y, Qian B, Chen H, Ma M, Su S, Geng H, Zhou WX, Guo X, Zhu WZ, Zhang M, Chen Z, Rensen PC, Hui CC, Wang Y, Shi B. Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome: A randomized trial. Cell Rep Med 2022; 3:100777. [PMID: 36220069 PMCID: PMC9589024 DOI: 10.1016/j.xcrm.2022.100777] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2022] [Revised: 07/24/2022] [Accepted: 09/20/2022] [Indexed: 11/30/2022]
Abstract
Overconsumption of carbohydrate-rich food combined with adverse eating patterns contributes to the increasing incidence of metabolic syndrome (MetS) in China. Therefore, we conducted a randomized trial to determine the effects of a low-carbohydrate diet (LCD), an 8-h time-restricted eating (TRE) schedule, and their combination on body weight and abdominal fat area (i.e., primary outcomes) and cardiometabolic outcomes in participants with MetS. Compared with baseline, all 3-month treatments significantly reduce body weight and subcutaneous fat area, but only TRE and combination treatment reduce visceral fat area (VFA), fasting blood glucose, uric acid (UA), and dyslipidemia. Furthermore, compared with changes of LCD, TRE and combination treatment further decrease body weight and VFA, while only combination treatment yields more benefits on glycemic control, UA, and dyslipidemia. In conclusion, without change of physical activity, an 8-h TRE with or without LCD can serve as an effective treatment for MetS (ClinicalTrials.gov: NCT04475822).
Collapse
Affiliation(s)
- Mingqian He
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Jingya Wang
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Qian Liang
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Meng Li
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Hui Guo
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Yue Wang
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Cuomu Deji
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Jing Sui
- Department of Endocrinology and International Medical Center, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Ya-wen Wang
- Biobank, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China,Department of Laboratory Medicine, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Yufeng Liu
- Biobank, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Yixuan Zheng
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Buyue Qian
- Network and Information Center, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Huaixi Chen
- Network and Information Center, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Mao Ma
- Physical Examination Center, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Shi Su
- Physical Examination Center, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Hui Geng
- Physical Examination Center, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Wen-xu Zhou
- Department of Internal Medicine, The Hospital of Xi’an JiaoTong University, No. 28, West Xianning Road, Xi’an, Shaanxi 710049, P.R. China
| | - Xiaoxiao Guo
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Wen-zhi Zhu
- Med-X institute, Center for Immunological and Metabolic Diseases, the First Affiliated Hospital of Xi’an JiaoTong University, Xi’an JiaoTong University, Xi’an, Shaanxi 710061, P.R. China
| | - Meng Zhang
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Ziyi Chen
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
| | - Patrick C.N. Rensen
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China,Department of Medicine, Division of Endocrinology, Leiden University Medical Center, P.O. Box 9600, 2300 Leiden, the Netherlands
| | - Chi-chung Hui
- Program in Developmental & Stem Cell Biology, The Hospital for Sick Children, and Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Yanan Wang
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China,Med-X institute, Center for Immunological and Metabolic Diseases, the First Affiliated Hospital of Xi’an JiaoTong University, Xi’an JiaoTong University, Xi’an, Shaanxi 710061, P.R. China,Corresponding author
| | - Bingyin Shi
- Department of Endocrinology, The First Affiliated Hospital of Xi’an JiaoTong University, No. 277, West Yanta Road, Xi’an, Shaanxi 710061, P.R. China,Corresponding author
| |
Collapse
|
3
|
Rahimi F, Pasdar Y, Kaviani M, Abbasi S, Fry H, Hekmatdoost A, Nikpayam O, Sohrab G, Rezaei M, Nachvak SM, Mohammadi R. Efficacy of the Synbiotic Supplementation on the Metabolic Factors in Patients with Metabolic Syndrome: A Randomized, Triple-Blind, Placebo-Controlled Trial. Int J Clin Pract 2022; 2022:2967977. [PMID: 35685524 PMCID: PMC9159159 DOI: 10.1155/2022/2967977] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Accepted: 03/08/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Metabolic syndrome is overwhelmingly increasing and is a significant risk factor for cardiovascular disorder, so effective treatment strategies are considered high priority. This study aimed to determine the effects of synbiotic supplementation on metabolic factors in patients with metabolic syndrome. METHODS In this triple-blind, randomized, placebo-controlled, clinical trial, 108 participants were divided into two groups to receive synbiotic supplementation or placebo for 12 weeks. All participants were also educated about maintaining a healthy lifestyle and consuming low-calorie nutritious meals, along with dietary intake and physical activity monitoring. Anthropometric measures, blood pressure, glycemic indices, lipid profile, hepatic enzymes, and hs-CRP were evaluated at the baseline and end of the trial. RESULTS Synbiotic supplementation significantly reduces fasting blood glucose (FBG) levels in the intervention group versus placebo group [-14.69 ± 15.11 mg/dl vs. -8.23 ± 7.90 mg/dl; p=0.007], but there was no difference between groups in other metabolic factors. CONCLUSIONS These findings suggest that synbiotic supplementation while following a healthy lifestyle and nutrition improved FBG in patients with metabolic syndrome.
Collapse
Affiliation(s)
- Fatemeh Rahimi
- Nutritional Sciences Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Yahya Pasdar
- Nutritional Sciences Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Mojtaba Kaviani
- School of Nutrition and Dietetics, Acadia University, Wolfville, NS, Canada
| | - Soheil Abbasi
- Nutritional Sciences Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Hillary Fry
- School of Nutrition and Dietetics, Acadia University, Wolfville, NS, Canada
| | - Azita Hekmatdoost
- Department of Clinical Nutrition and Dietetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Omid Nikpayam
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Clinical Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Golbon Sohrab
- Department of Clinical Nutrition and Dietetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mansoaur Rezaei
- Department of Biostatistics, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Seyed Mostafa Nachvak
- Nutritional Sciences Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Reza Mohammadi
- Food Sciences Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
| |
Collapse
|
4
|
Stadler JT, Marsche G. Dietary Strategies to Improve Cardiovascular Health: Focus on Increasing High-Density Lipoprotein Functionality. Front Nutr 2021; 8:761170. [PMID: 34881279 PMCID: PMC8646038 DOI: 10.3389/fnut.2021.761170] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 10/28/2021] [Indexed: 12/12/2022] Open
Abstract
Cardiovascular disease is one of the leading causes of morbidity and mortality worldwide, with increasing incidence. A cornerstone of cardiovascular disease prevention is lifestyle modification through dietary changes to influence various risk factors such as obesity, hypertension and diabetes. The effects of diet on cardiovascular health are complex. Some dietary components and metabolites directly affect the composition and structure of high-density lipoproteins (HDL) and increase anti-inflammatory and vasoprotective properties. HDLs are composed of distinct subpopulations of particles of varying size and composition that have several dynamic and context-dependent functions. The identification of potential dietary components that improve HDL functionality is currently an important research goal. One of the best-studied diets for cardiovascular health is the Mediterranean diet, consisting of fish, olive oil, fruits, vegetables, whole grains, legumes/nuts, and moderate consumption of alcohol, most commonly red wine. The Mediterranean diet, especially when supplemented with extra virgin olive oil rich in phenolic compounds, has been shown to markedly improve metrics of HDL functionality and reduce the burden, or even prevent the development of cardiovascular disease. Particularly, the phenolic compounds of extra virgin olive oil seem to exert the significant positive effects on HDL function. Moreover, supplementation of anthocyanins as well as antioxidants such as lycopene or the omega-3 fatty acid eicosapentaenoic acid improve parameters of HDL function. In this review, we aim to highlight recent discoveries on beneficial dietary patterns as well as nutritional components and their effects on cardiovascular health, focusing on HDL function.
Collapse
Affiliation(s)
- Julia T. Stadler
- Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
| | - Gunther Marsche
- Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
| |
Collapse
|
5
|
Sanllorente A, Soria-Florido MT, Castañer O, Lassale C, Salas-Salvadó J, Martínez-González MÁ, Subirana I, Ros E, Corella D, Estruch R, Tinahones FJ, Hernáez Á, Fitó M. A lifestyle intervention with an energy-restricted Mediterranean diet and physical activity enhances HDL function: a substudy of the PREDIMED-Plus randomized controlled trial. Am J Clin Nutr 2021; 114:1666-1674. [PMID: 34582548 DOI: 10.1093/ajcn/nqab246] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Accepted: 06/30/2021] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Consumption of a Mediterranean diet, adequate levels of physical activity, and energy-restricted lifestyle interventions have been individually associated with improvements in HDL functions. Evidence of intensive interventions with calorie restriction and physical activity is, however, scarce. OBJECTIVES To determine whether an intensive lifestyle intervention with an energy-restricted Mediterranean diet plus physical activity enhanced HDL function compared to a non-hypocaloric Mediterranean eating pattern without physical activity. METHODS In 391 older adults with metabolic syndrome (mean age, 65 years; mean BMI, 33.3 kg/m2) from 1 of the Prevención con Dieta Mediterránea-Plus trial centers, we evaluated the impact of a 6-month intervention with an energy-restricted Mediterranean diet plus physical activity (intensive lifestyle; n = 190) relative to a nonrestrictive Mediterranean diet without physical activity (control; n = 201) on a set of HDL functional traits. These included cholesterol efflux capacity, HDL oxidative/inflammatory index, HDL oxidation, and levels of complement component 3, serum amyloid A, sphingosine-1-phosphate, triglycerides, and apolipoproteins A-I, A-IV, C-III, and E in apoB-depleted plasma. RESULTS The intensive-lifestyle intervention participants displayed greater 6-month weight reductions (-3.83 kg; 95% CI: -4.57 to -3.09 kg) but no changes in HDL cholesterol compared with control-diet participants. Regarding HDL functional traits, the intensive lifestyle decreased triglyceride levels (-0.15 mg/g protein; 95% CI: -0.29 to -0.014 mg/g protein) and apoC-III (-0.11 mg/g protein; 95% CI: -0.18 to -0.026 mg/g protein) compared to the control diet, with weight loss being the essential mediator (proportions of mediation were 77.4% and 72.1% for triglycerides and apoC-III levels in HDL, respectively). CONCLUSIONS In older adults with metabolic syndrome, an energy-restricted Mediterranean diet plus physical activity improved the HDL triglyceride metabolism compared with a nonrestrictive Mediterranean diet without physical activity. This trial is registered at isrctn.com as ISRCTN89898870.
Collapse
Affiliation(s)
- Albert Sanllorente
- Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.,PhD Program in Biomedicine, Universitat Pompeu Fabra, Barcelona, Spain.,Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Olga Castañer
- Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.,Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Camille Lassale
- Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.,Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Jordi Salas-Salvadó
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,Unitat de Nutrició Humana, Departament de Bioquimica i Biotecnologia, Universitat Rovira i Virgili, Reus, Spain.,Institut d'Investigació Pere Virgili, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - Miguel Ángel Martínez-González
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain.,Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA
| | - Isaac Subirana
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.,Cardiovascular Epidemiology and Genetics Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - Emilio Ros
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Barcelona, Spain.,August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
| | - Dolores Corella
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,Department of Preventive Medicine, Universidad de Valencia, Valencia, Spain
| | - Ramón Estruch
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.,Department of Internal Medicine, Hospital Clínic, Barcelona, Spain
| | - Francisco J Tinahones
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,Virgen de la Victoria Hospital, Department of Endocrinology, Biomedical Research Institute of Málaga, University of Málaga, Málaga, Spain
| | - Álvaro Hernáez
- Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.,Blanquerna School of Health Sciences, Universitat Ramon Llull, Barcelona, Spain.,Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway
| | - Montserrat Fitó
- Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.,Consorcio Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
6
|
Tereshkina YA, Kostryukova LV, Torkhovskaya TI, Khudoklinova YY, Tikhonova EG. [Plasma high density lipoproteins phospholipds as an indirect indicator of their cholesterol efflux capacity - new suspected atherosclerosis risk factor]. BIOMEDIT︠S︡INSKAI︠A︡ KHIMII︠A︡ 2021; 67:119-129. [PMID: 33860768 DOI: 10.18097/pbmc20216702119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
High density lipoproteins (HDL) are a unique natural structure, protecting the body from the development of atherosclerotic vascular lesions and cardiovascular diseases due to this ability to remove cholesterol from cells. Plasma HDL level estimated by their cholesterol content, is a common lipid parameter, and its decrease is considered as an established atherosclerosis risk factor. However, a number of studies have shown the absence of positive clinical effects after drug-induced increase in HDL cholesterol. There is increasing evidence that not only HDL concentration, but also HDL properties, considered in this review are important. Many studies showed the decrease of HDL cholesterol efflux capacity in patients with coronary heart diseases and its association with disease severity. Some authors consider a decrease of this HDL capacity as a new additional risk factor of atherosclerosis. The review summarizes existing information on various protein and lipid components of HDL with a primary emphasis on the HDL. Special attention is paid to correlation between the HDL cholesterol efflux capacity and HDL phospholipids and the ratio "phospholipids/free cholesterol". The accumulated information indicates importance of evaluation in the HDL fraction not only in terms of their cholesterol, but also phospholipids. In addition to the traditionally used lipid criteria, this would provide more comprehensive information about the activity of the reverse cholesterol transport process in the body and could contribute to the targeted correction of the detected disorders.
Collapse
|
7
|
Borgundvaag E, Mak J, Kramer CK. Metabolic Impact of Intermittent Fasting in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Interventional Studies. J Clin Endocrinol Metab 2021; 106:902-911. [PMID: 33319233 DOI: 10.1210/clinem/dgaa926] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Indexed: 02/11/2023]
Abstract
CONTEXT Intermittent fasting (IF) has been proposed as a weight-loss strategy with additional cardiometabolic benefits in individuals with obesity. Despite its growing popularity, the effect of IF in patients with type 2 diabetes (T2DM) remains unclear. OBJECTIVE We conducted a systematic review and meta-analysis to evaluate the metabolic impact of IF compared to standard diet in patients with T2DM. METHODS Embase, PubMed, and clinicaltrials.gov between 1950 and August 12, 2020 were searched for randomized, diet-controlled studies evaluating any IF intervention in adults with T2DM. We examined the impact of IF on weight loss and glucose-lowering by calculating pooled estimates of the absolute differences in body weight and glycated hemoglobin A1c (HbA1c) compared to a control group using a random-effects model. RESULTS Seven studies (n = 338 participants; mean body mass index [BMI] 35.65, mean baseline HbA1c 8.8%) met our inclusion criteria. IF induced a greater decrease in body weight by -1.89 kg (95% CI, -2.91 to -0.86 kg) compared to a regular diet, with no significant between-study heterogeneity (I2 21.0%, P = .28). The additional weight loss induced by IF was greater in studies with a heavier population (BMI > 36) (-3.43 kg [95% CI, -5.72 to -1.15 kg]) and in studies of shorter duration (≤ 4 months) (-3.73 kg [95% CI, -7.11 to -0.36 kg]). IF was not associated with further reduction in HbA1c compared to a standard diet (HbA1c -0.11% [95% CI, -0.38% to 0.17%]). CONCLUSION Current evidence suggests that IF is associated with greater weight loss in patients with T2DM compared with a standard diet, with a similar impact on glycemic control.
Collapse
Affiliation(s)
- Emily Borgundvaag
- Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Jessica Mak
- Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada
- Department of Internal Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Caroline K Kramer
- Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada
- Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| |
Collapse
|
8
|
Zhou E, Li Z, Nakashima H, Choukoud A, Kooijman S, Berbée JFP, Rensen PCN, Wang Y. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Pharmacol Res 2021; 167:105524. [PMID: 33667684 DOI: 10.1016/j.phrs.2021.105524] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Revised: 02/19/2021] [Accepted: 02/28/2021] [Indexed: 12/13/2022]
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, by increasing hepatic low density lipoprotein (LDL) receptor (LDLR) levels, has emerged as a strategy to reduce atherosclerosis by lowering circulating very low density lipoprotein (VLDL)-cholesterol. We hypothesized that the therapeutic effectiveness of PCSK9 inhibition can be increased by accelerating the generation of VLDL remnants, which typically have a high affinity for the LDLR. Therefore, we aimed to investigate whether accelerating lipolytic processing of VLDL by brown fat activation can further lower (V)LDL and reduce atherosclerosis on top of PCSK9 inhibition. APOE*3-Leiden.CETP mice were fed a Western-type diet and treated with the anti-PCSK9 antibody alirocumab or saline. After 2 weeks, both groups of mice were randomized to receive either the selective β3-adrenergic receptor (AR) agonist CL316,243 to activate brown fat or saline for 3 additional weeks to evaluate VLDL clearance or 12 additional weeks to analyze atherosclerosis development. β3-AR agonism and alirocumab combined decreased (V)LDL-cholesterol compared to alirocumab alone, which was explained by an accelerated plasma clearance of VLDL-cholesteryl esters that were mainly taken up by the liver. In addition, the combination promoted the transfer of VLDL-phospholipids to HDL to a higher extent than alirocumab alone, accompanied by higher plasma HDL-cholesterol levels and increased cholesterol efflux capacity. Consequently, combination treatment largely reduced atherosclerotic lesion area compared to vehicle. Together, β3-AR agonism enhances the lipoprotein-modulating effects of alirocumab to further improve dyslipidemia and non-significantly further attenuate atherosclerosis development. Our findings demonstrate that brown fat activation may enhance the therapeutic effects of PCSK9 inhibition in dyslipidemia.
Collapse
Affiliation(s)
- Enchen Zhou
- Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Zhuang Li
- Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Hiroyuki Nakashima
- Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Ahlam Choukoud
- Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Sander Kooijman
- Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Jimmy F P Berbée
- Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Patrick C N Rensen
- Department of Endocrinology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an, China; Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Yanan Wang
- Department of Endocrinology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an, China; Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
| |
Collapse
|
9
|
Stadler JT, Marsche G. Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function. Int J Mol Sci 2020; 21:E8985. [PMID: 33256096 PMCID: PMC7731239 DOI: 10.3390/ijms21238985] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 11/23/2020] [Accepted: 11/24/2020] [Indexed: 02/07/2023] Open
Abstract
In obese individuals, atherogenic dyslipidemia is a very common and important factor in the increased risk of cardiovascular disease. Adiposity-associated dyslipidemia is characterized by low high-density lipoprotein cholesterol (HDL-C) levels and an increase in triglyceride-rich lipoproteins. Several factors and mechanisms are involved in lowering HDL-C levels in the obese state and HDL quantity and quality is closely related to adiponectin levels and the bioactive lipid sphingosine-1-phosphate. Recent studies have shown that obesity profoundly alters HDL metabolism, resulting in altered HDL subclass distribution, composition, and function. Importantly, weight loss through gastric bypass surgery and Mediterranean diet, especially when enriched with virgin olive oil, is associated with increased HDL-C levels and significantly improved metrics of HDL function. A thorough understanding of the underlying mechanisms is crucial for a better understanding of the impact of obesity on lipoprotein metabolism and for the development of appropriate therapeutic approaches. The objective of this review article was to summarize the newly identified changes in the metabolism, composition, and function of HDL in obesity and to discuss possible pathophysiological consequences.
Collapse
Affiliation(s)
- Julia T. Stadler
- Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, 8010 Graz, Austria
| | - Gunther Marsche
- Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, 8010 Graz, Austria
| |
Collapse
|
10
|
Hafiane A, Favari E, Daskalopoulou SS, Vuilleumier N, Frias MA. High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases. Metabolism 2020; 104:154141. [PMID: 31923386 DOI: 10.1016/j.metabol.2020.154141] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/23/2019] [Accepted: 01/05/2020] [Indexed: 12/22/2022]
Abstract
Functional assessment of cholesterol efflux capacity (CEC) to high-density lipoprotein (HDL) is an emerging tool for evaluating morbidity and mortality associated with cardiovascular disease (CVD). By promoting macrophage reverse cholesterol transport (RCT), HDL-mediated CEC is believed to play an important role in atherosclerotic lesion progression in the vessel wall. Furthermore, recent evidence indicates that the typical inverse associations between various forms of CEC and CV events may be strongly modulated by environmental systemic factors and traditional CV risk factors, in addition to autoimmune diseases. These factors influence the complex and dynamic composition of HDL particles, which in turn positively or negatively affect HDL-CEC. Herein, we review recent findings connecting HDL-CEC to traditional CV risk factors and cardiometabolic conditions (non-autoimmune diseases) as well as autoimmune diseases, with a specific focus on how these factors may influence the associations between HDL-CEC and CVD risk.
Collapse
Affiliation(s)
- Anouar Hafiane
- Department of Medicine, Faculty of Medicine, Research Institute of the McGill University Health Centre, McGill University, 1001 Decarie Blvd, Bloc E01. 3370H, Montréal, Qc H4A 3J1, Canada.
| | - Elda Favari
- Department of Food and Drug, University of Parma, Parco Area delle Scienze, 27/A, 43124 Parma, Italy.
| | - Stella S Daskalopoulou
- Department of Medicine, Division of Internal Medicine, McGill University, Research Institute of the McGill University Health Centre, 1001 Decarie Blvd, EM1.2230, Montreal, Quebec H4A 3J1, Canada.
| | - Nicolas Vuilleumier
- Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland; Division of Laboratory Medicine, Department of Medical Specialties, Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
| | - Miguel A Frias
- Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland; Division of Laboratory Medicine, Department of Medical Specialties, Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
| |
Collapse
|
11
|
Contreras-Duarte S, Carvajal L, Garchitorena MJ, Subiabre M, Fuenzalida B, Cantin C, Farías M, Leiva A. Gestational Diabetes Mellitus Treatment Schemes Modify Maternal Plasma Cholesterol Levels Dependent to Women´s Weight: Possible Impact on Feto-Placental Vascular Function. Nutrients 2020; 12:E506. [PMID: 32079298 PMCID: PMC7071311 DOI: 10.3390/nu12020506] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Accepted: 02/11/2020] [Indexed: 12/19/2022] Open
Abstract
: Gestational diabetes mellitus (GDM) associates with fetal endothelial dysfunction (ED), which occurs independently of adequate glycemic control. Scarce information exists about the impact of different GDM therapeutic schemes on maternal dyslipidemia and obesity and their contribution to the development of fetal-ED. The aim of this study was to evaluate the effect of GDM-treatments on lipid levels in nonobese (N) and obese (O) pregnant women and the effect of maternal cholesterol levels in GDM-associated ED in the umbilical vein (UV). O-GDM women treated with diet showed decreased total cholesterol (TC) and low-density lipoproteins (LDL) levels with respect to N-GDM ones. Moreover, O-GDM women treated with diet in addition to insulin showed higher TC and LDL levels than N-GDM women. The maximum relaxation to calcitonin gene-related peptide of the UV rings was lower in the N-GDM group compared to the N one, and increased maternal levels of TC were associated with even lower dilation in the N-GDM group. We conclude that GDM-treatments modulate the TC and LDL levels depending on maternal weight. Additionally, increased TC levels worsen the GDM-associated ED of UV rings. This study suggests that it could be relevant to consider a specific GDM-treatment according to weight in order to prevent fetal-ED, as well as to consider the possible effects of maternal lipids during pregnancy.
Collapse
Affiliation(s)
- Susana Contreras-Duarte
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
| | - Lorena Carvajal
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
| | - María Jesús Garchitorena
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
| | - Mario Subiabre
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
| | - Bárbara Fuenzalida
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
| | - Claudette Cantin
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
| | - Marcelo Farías
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
| | - Andrea Leiva
- Department of Obstetrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile; (L.C.); (M.J.G.); (M.S.); (B.F.); (C.C.); (M.F.)
- School of Medical Technology, Health Sciences Faculty, Universidad San Sebastian, Santiago 8330024, Chile
| |
Collapse
|
12
|
van Eyk HJ, Blauw LL, Bizino MB, Wang Y, van Dijk KW, de Mutsert R, Smit JWA, Lamb HJ, Jazet IM, Rensen PCN. Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. Sci Rep 2019; 9:9996. [PMID: 31292457 PMCID: PMC6620358 DOI: 10.1038/s41598-019-45593-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 06/06/2019] [Indexed: 12/29/2022] Open
Abstract
Cholesteryl ester transfer protein (CETP) is mainly expressed by Kupffer cells in the liver. A reduction of hepatic triglyceride content (HTGC) by pioglitazone or caloric restriction is accompanied by a decrease in circulating CETP. Since GLP-1 analogues also reduce HTGC, we assessed whether liraglutide decreases CETP. Furthermore, we investigated the association between HTGC and CETP in a population-based cohort. In a placebo-controlled trial, 50 patients with type 2 diabetes were randomly assigned to treatment with liraglutide or placebo added to standard care. In this trial and in 1,611 participants of the Netherlands Epidemiology of Obesity (NEO) study, we measured HTGC and circulating CETP by proton magnetic resonance spectroscopy and ELISA, respectively. The HTGC was decreased in the liraglutide group (-6.3%; 95%CI of difference [-9.5, -3.0]) but also in the placebo group (-4.0%; 95%CI[-6.0, -2.0]), without between-group differences. CETP was not decreased by liraglutide (-0.05 µg/mL; 95%CI[-0.13, 0.04]) or placebo (-0.04 µg/mL; 95%CI[-0.12, 0.04]). No association was present between HTGC and CETP at baseline (β: 0.002 µg/mL per %TG, 95%CI[-0.005, 0.009]) and between the changes after treatment with liraglutide (β: 0.003 µg/mL per %TG, 95%CI[-0.010, 0.017]) or placebo (β: 0.006 µg/mL per %TG, 95%CI[-0.012,0.024]). Also, in the cohort n o association between HTGC and CETP was present (β: -0.001 µg/mL per SD TG, 95%CI[-0.005, 0.003]). A reduction of HTGC after treatment with liraglutide or placebo does not decrease circulating CETP. Also, no association between HTGC and CETP was present in a large cohort. These findings indicate that circulating CETP is not determined by HTGC.Clinical Trial Registration: Clinicaltrials.gov (NCT01761318).
Collapse
Affiliation(s)
- Huub J van Eyk
- Department Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
- Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands.
| | - Lisanne L Blauw
- Department Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
- Department Epidemiology, LUMC, Leiden, The Netherlands
| | - Maurice B Bizino
- Department Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
- Department Radiology, LUMC, Leiden, The Netherlands
| | - Yanan Wang
- Department Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
| | - Ko Willems van Dijk
- Department Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
- Department Human Genetics, LUMC, Leiden, The Netherlands
| | | | - Johannes W A Smit
- Department Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Hildo J Lamb
- Department Radiology, LUMC, Leiden, The Netherlands
| | - Ingrid M Jazet
- Department Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
| | - Patrick C N Rensen
- Department Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
| |
Collapse
|
13
|
Mathew AV, Li L, Byun J, Guo Y, Michailidis G, Jaiswal M, Chen YE, Pop-Busui R, Pennathur S. Therapeutic Lifestyle Changes Improve HDL Function by Inhibiting Myeloperoxidase-Mediated Oxidation in Patients With Metabolic Syndrome. Diabetes Care 2018; 41:2431-2437. [PMID: 30201848 PMCID: PMC6196832 DOI: 10.2337/dc18-0049] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2018] [Accepted: 08/17/2018] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Phagocyte-derived myeloperoxidase (MPO) and proinflammatory HDL are associated with metabolic syndrome (MetS) and increased cardiovascular disease risk. Therapeutic lifestyle changes (TLCs), such as a Mediterranean diet and exercise, decrease this risk. However, the link among TLCs, HDL, and MPO-mediated oxidative stress remains unclear. RESEARCH DESIGN AND METHODS In this study, we characterized changes in cholesterol efflux capacity (CEC), a metric of HDL function; MPO-mediated oxidation; and the HDL proteomic profile in 25 patients with MetS who underwent 12 weeks of TLCs. RESULTS After 12 weeks, before significant changes to HDL levels, most MetS components improved as a result of the TLCs. CEC was significantly increased, and HDL MPO oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, were decreased with TLCs. The changes in CEC were inversely related to the unit changes in 3-chlorotyrosine after we controlled for changes in the other MetS components. TLCs did not remodel the HDL proteome. CONCLUSIONS In summary, TLCs improved HDL function by inhibiting MPO-mediated oxidative stress even before appreciable changes in HDL levels.
Collapse
Affiliation(s)
- Anna V Mathew
- Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
| | - Lei Li
- Peking University Health Sciences Center, Beijing, China
| | - Jaeman Byun
- Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
| | - Yanhong Guo
- Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI
| | | | - Mamta Jaiswal
- Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
| | - Y Eugene Chen
- Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI
| | - Rodica Pop-Busui
- Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
| | - Subramaniam Pennathur
- Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI .,Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI
| |
Collapse
|
14
|
Talbot CPJ, Plat J, Joris PJ, Konings M, Kusters YHAM, Schalkwijk CG, Ritsch A, Mensink RP. HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men. Atherosclerosis 2018; 274:23-28. [PMID: 29747087 DOI: 10.1016/j.atherosclerosis.2018.04.029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 04/04/2018] [Accepted: 04/24/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND AND AIMS Obesity is associated with a lower HDL-mediated cholesterol efflux from macrophages and a higher CETP (cholesteryl ester transfer protein) activity, but effects of weight loss are not clear. In addition, associations with visceral and subcutaneous adipose tissue are not known. We therefore investigated effects of diet-induced weight loss on HDL-mediated cholesterol efflux and cholesterol ester (CE) transfer in abdominally obese men. Differences between normal-weight and abdominally obese men were also examined. METHODS Twenty-five apparently healthy, normal-weight men (waist circumference: <94 cm) and 52 abdominally obese men (waist circumference: 102-110 cm) were included. Abdominally obese subjects were randomly allocated to a dietary weight-loss intervention group or a no-weight loss control group. Individuals from the intervention group followed a very-low-calorie diet for 6 weeks to obtain a waist circumference below 102 cm, followed by a 2-week weight-stable period. Cholesterol efflux was measured in BODIPY-labeled murine J774 macrophages. CE transfer was measured by quantifying the transfer of CE from radiolabeled exogenous HDL to apoB-containing lipoproteins. RESULTS Cholesterol efflux capacity was 9 percentage point (pp) lower in abdominally obese than in normal-weight men (p≤0.001), while CE transfer was 5 pp higher (p≤0.01). Diet-induced weight-loss of 10.3 kg did not change cholesterol efflux and CE transfer. In addition, stepwise regression analysis did not suggest that the different fat depots are differently related to efflux capacity and CE transfer. CONCLUSIONS After a 2-week weight-stable period, dietary weight loss of 10 kg did not improve ABCA1-mediated cholesterol efflux and CE transfer in abdominally obese men.
Collapse
Affiliation(s)
- Charlotte P J Talbot
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
| | - Jogchum Plat
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Peter J Joris
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Maurice Konings
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Yvo H A M Kusters
- Department of Internal Medicine, CARIM (School for Cardiovascular Diseases), Maastricht University Medical Center, Maastricht, Netherlands
| | - Casper G Schalkwijk
- Department of Internal Medicine, CARIM (School for Cardiovascular Diseases), Maastricht University Medical Center, Maastricht, Netherlands
| | | | - Ronald P Mensink
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
15
|
Yu Q, Liu R, Han L, Zhang G, Guan H, Pan Q, Wang S, Liu E. Dietary restriction slightly affects glucose homeostasis and delays plasma cholesterol removal in rabbits with dietary lipid lowering. Appl Physiol Nutr Metab 2018; 43:996-1002. [PMID: 29658290 DOI: 10.1139/apnm-2017-0876] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Dietary restriction (DR) has been reported to have beneficial effects on atherosclerotic progression as well as lipid and glucose metabolism, but little is known about whether these effects can be enhanced or weakened by dietary lipid lowering. Here, after 12 weeks of high-cholesterol diet feeding, hypercholesterolemic rabbits were fed with either a standard chow diet ad libitum (AL) or a standard chow diet with DR for 16 weeks of dietary lipid lowering. We found that the DR group exhibited a loss of body weight, smaller internal organs, and reduced fat mass, while the AL group accumulated more subcutaneous fat than the baseline group. DR treatment slightly worsened glucose tolerance but enhanced insulin sensitivity, and a slight effect of DR on insulin secretion was also observed. After dietary cholesterol withdrawal, rabbits showed persistent lowering of total cholesterol and triglycerides in plasma. However, the DR group had significantly higher plasma total cholesterol than the AL group at most time points during weeks 7 to 16 of lipid lowering. Although both the AL and DR groups developed more severe atherosclerosis than the baseline group, DR did not improve atherosclerotic progression or the accumulation of macrophages and smooth muscle cells. We conclude that DR affected glucose and lipid metabolism but did not ameliorate atherosclerosis in rabbits when associated with lipid lowering by dietary cholesterol withdrawal.
Collapse
Affiliation(s)
- Qi Yu
- a Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China.,b Institute of Material Medical, School of Pharmacy, The Fourth Military Medical University, Xi'an 710032, China
| | - Ruihan Liu
- c Department of Pathology, Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China
| | - Lijuan Han
- a Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China
| | - Guangwei Zhang
- a Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China
| | - Hua Guan
- a Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China
| | - Qi Pan
- a Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China
| | - Siwang Wang
- b Institute of Material Medical, School of Pharmacy, The Fourth Military Medical University, Xi'an 710032, China
| | - Enqi Liu
- a Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China
| |
Collapse
|
16
|
Heffron SP, Lin BX, Parikh M, Scolaro B, Adelman SJ, Collins HL, Berger JS, Fisher EA. Changes in High-Density Lipoprotein Cholesterol Efflux Capacity After Bariatric Surgery Are Procedure Dependent. Arterioscler Thromb Vasc Biol 2018; 38:245-254. [PMID: 29162605 PMCID: PMC5746465 DOI: 10.1161/atvbaha.117.310102] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2017] [Accepted: 11/03/2017] [Indexed: 01/05/2023]
Abstract
OBJECTIVE High-density lipoprotein cholesterol efflux capacity (CEC) is inversely associated with incident cardiovascular events, independent of high-density lipoprotein cholesterol. Obesity is often characterized by impaired high-density lipoprotein function. However, the effects of different bariatric surgical techniques on CEC have not been compared. This study sought to determine the effects of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on CEC. APPROACH AND RESULTS We prospectively studied severely obese, nondiabetic, premenopausal Hispanic women not using lipid medications undergoing RYGB (n=31) or SG (n=36). Subjects were examined before and at 6 and 12 months after surgery. There were no differences in baseline characteristics between surgical groups. Preoperative CEC correlated most strongly with Apo A1 (apolipoprotein A1) concentration but did not correlate with body mass index, waist:hip, high-sensitivity C-reactive protein, or measures of insulin resistance. After 6 months, SG produced superior response in high-density lipoprotein cholesterol and Apo A1 quantity, as well as global and non-ABCA1 (ATP-binding cassette transporter A1)-mediated CEC (P=0.048, P=0.018, respectively) versus RYGB. In multivariable regression models, only procedure type was predictive of changes in CEC (P=0.05). At 12 months after SG, CEC was equivalent to that of normal body mass index control subjects, whereas it remained impaired after RYGB. CONCLUSIONS SG and RYGB produce similar weight loss, but contrasting effects on CEC. These findings may be relevant in discussions about the type of procedure that is most appropriate for a particular obese patient. Further study of the mechanisms underlying these changes may lead to improved understanding of the factors governing CEC and potential therapeutic interventions to maximally reduce cardiovascular disease risk in both obese and nonobese patients.
Collapse
Affiliation(s)
- Sean P Heffron
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.).
| | - Bing-Xue Lin
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.)
| | - Manish Parikh
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.)
| | - Bianca Scolaro
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.)
| | - Steven J Adelman
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.)
| | - Heidi L Collins
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.)
| | - Jeffrey S Berger
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.)
| | - Edward A Fisher
- From the Department of Medicine, Leon H. Charney Division of Cardiology and the Center for the Prevention of Cardiovascular Disease (S.P.H., B.L., J.S.B., E.A.F.), Department of Surgery (M.P.), and Department of Surgery, Division of Vascular Surgery, New York University Langone Medical Center (J.S.B.), New York University School of Medicine, New York; Department of Food Science and Experimental Nutrition, University of Sao Paulo, Brazil (B.S.); and Vascular Strategies LLC, Plymouth Meeting, PA (S.J.A., H.L.C.)
| |
Collapse
|
17
|
Talbot CP, Plat J, Ritsch A, Mensink RP. Determinants of cholesterol efflux capacity in humans. Prog Lipid Res 2018; 69:21-32. [PMID: 29269048 DOI: 10.1016/j.plipres.2017.12.001] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 12/09/2017] [Accepted: 12/11/2017] [Indexed: 12/26/2022]
|
18
|
Bakker LEH, Boon MR, Annema W, Dikkers A, van Eyk HJ, Verhoeven A, Mayboroda OA, Jukema JW, Havekes LM, Meinders AE, Willems van Dijk K, Jazet IM, Tietge UJF, Rensen PCN. HDL functionality in South Asians as compared to white Caucasians. Nutr Metab Cardiovasc Dis 2016; 26:697-705. [PMID: 27052926 DOI: 10.1016/j.numecd.2016.02.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Revised: 01/31/2016] [Accepted: 02/10/2016] [Indexed: 12/28/2022]
Abstract
BACKGROUND AND AIMS South Asians have an exceptionally high risk of developing cardiovascular disease compared to white Caucasians. A contributing factor might be dysfunction of high density lipoprotein (HDL). We aimed to compare HDL function in different age groups of both ethnicities. METHODS AND RESULTS HDL functionality with respect to cholesterol efflux, anti-oxidation and anti-inflammation was determined using fasting, apoB-depleted, plasma samples from South Asian and white Caucasian neonates (n = 14 each), adolescent healthy men (n = 12 each, 18-25 y), and adult overweight men (n = 12 each, 40-50 y). Adolescents were subjected to a 5-day high fat high calorie diet (HCD) and adults to an 8-day very low calorie diet (LCD). Additionally, HDL composition was measured in adolescents and adults using (1)H-NMR spectroscopy. Anti-oxidative capacity was lower in South Asian adults before LCD (19.4 ± 2.1 vs. 25.8 ± 1.2%, p = 0.045, 95%-CI = [0.1; 12.7]) and after LCD (16.4 ± 2.4 vs. 27.6 ± 2.7%, p = 0.001, 95%-CI = [4.9; 17.5]). Anti-inflammatory capacity was reduced in South Asian neonates (23.8 ± 1.2 vs. 34.9 ± 1.3%, p = 0.000001, 95%-CI = [-14.6; -7.5]), and was negatively affected by an 8-day LCD only in South Asian adults (-12.2 ± 4.3%, p = 0.005, 95%-CI = [-5.9; -1.2]). Cholesterol efflux capacity was increased in response to HCD in adolescents (South Asians: +6.3 ± 2.9%, p = 0.073, 95%-CI = [-0.02; 0.46], Caucasians: +11.8 ± 3.4%, p = 0.002, 95%-CI = [0.17;0.65]) and decreased after LCD in adults (South Asians: -10.3 ± 2.4%, p < 0.001, 95%-CI = [-0.57; -0.20], Caucasians: -13.7 ± 1.9%, p < 0.00001, 95%-CI = [-0.67; -0.33]). Although subclass analyses of HDL showed no differences between ethnicities, cholesterol efflux correlated best with cholesterol and phospholipid within small HDL compared to other HDL subclasses and constituents. CONCLUSION Impaired HDL functionality in South Asians may be a contributing factor to their high CVD risk. CLINICAL TRIAL REGISTRATION NTR 2473 (URL: http://www.trialregister.nl/).
Collapse
Affiliation(s)
- L E H Bakker
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
| | - M R Boon
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands.
| | - W Annema
- Dept. Pediatrics, University Medical Center Groningen, Groningen, The Netherlands; Top Institute Food and Nutrition, Wageningen, The Netherlands
| | - A Dikkers
- Dept. Pediatrics, University Medical Center Groningen, Groningen, The Netherlands
| | - H J van Eyk
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
| | - A Verhoeven
- Center for Proteomics and Metabolomics, LUMC, Leiden, The Netherlands
| | - O A Mayboroda
- Center for Proteomics and Metabolomics, LUMC, Leiden, The Netherlands
| | - J W Jukema
- Dept. Cardiology, LUMC, Leiden, The Netherlands
| | - L M Havekes
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands; Dept. Cardiology, LUMC, Leiden, The Netherlands
| | - A E Meinders
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
| | - K Willems van Dijk
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Dept. Human Genetics, LUMC, Leiden, The Netherlands
| | - I M Jazet
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
| | - U J F Tietge
- Dept. Pediatrics, University Medical Center Groningen, Groningen, The Netherlands; Top Institute Food and Nutrition, Wageningen, The Netherlands
| | - P C N Rensen
- Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
| |
Collapse
|
19
|
Hansel B, Bonnefont-Rousselot D, Orsoni A, Bittar R, Giral P, Roussel R, Marre M, Mohammedi K, Bruckert E, Chapman MJ, Kontush A. Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels. J Clin Lipidol 2016; 10:1172-81. [PMID: 27678434 DOI: 10.1016/j.jacl.2016.05.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Revised: 04/25/2016] [Accepted: 05/06/2016] [Indexed: 11/25/2022]
Abstract
BACKGROUND Metabolic syndrome (MetS) is associated with altered lipoprotein metabolism and impairment in the functionality of small, dense high-density lipoprotein (HDL) particles secondary to compositional alterations. OBJECTIVE The objective of this study was to investigate the capacity of a lifestyle program to improve the composition and antioxidative function (AOX) of small dense HDL3c in MetS. METHODS Patients with MetS (n = 33) not taking lipid-lowering drugs were recruited to follow a 12-week educational program to reduce caloric intake and to increase physical activity. HDL subfractions were preparatively isolated by isopycnic density-gradient ultracentrifugation. AOX of HDL3c was assessed as its capacity to inhibit low-density lipoprotein oxidation induced by an azoinitiator. RESULTS AOX of HDL3c was significantly improved (mean reduction in the propagation rate of low-density lipoprotein oxidation by HDL3c, -6.8%, P = .03) and systemic oxidative stress, assessed as plasma levels of 8-isoprostanes, tended to decrease in normocholesterolemic MetS patients (low-density lipoprotein cholesterol [LDL-C] < 130 mg/dL) but not in patients with elevated LDL-C levels and in the whole study population. In both the whole study population and the normocholesterolemic subgroup, lifestyle intervention resulted in a significant degree of normalization of HDL3c composition, (enrichment in apolipoprotein A-I and cholesteryl esters, depletion in triglycerides), which was more pronounced at LDL-C < 130 mg/dL. CONCLUSION In patients with MetS, a lifestyle program improves AOX of small, dense HDL in subjects with normal LDL-C levels. Correction of HDL composition, involving partial normalization of apoA-I content and core lipid composition, 2 central features of the lipid hydroperoxide-inactivating capacity of HDL, may account for this effect.
Collapse
Affiliation(s)
- Boris Hansel
- Département d'Endocrinologie, Diabétologie et Nutrition, DHU FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France; INSERM U1138, Centre de Recherche des Cordeliers, Paris, France; Université Paris-Diderot, Paris 7, Paris, France.
| | - Dominique Bonnefont-Rousselot
- Service de Biochimie Métabolique, Groupe hospitalier Pitié-Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; INSERM UMRS 1166 ICAN, Université Pierre et Marie Curie Paris 6, Hôpital de la Pitie, Paris, France; Faculté de Pharmacie, Université Paris Descartes, Paris, France
| | - Alexina Orsoni
- INSERM UMRS 1166 ICAN, Université Pierre et Marie Curie Paris 6, Hôpital de la Pitie, Paris, France
| | - Randa Bittar
- Service de Biochimie Métabolique, Groupe hospitalier Pitié-Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; INSERM UMRS 1166 ICAN, Université Pierre et Marie Curie Paris 6, Hôpital de la Pitie, Paris, France
| | - Philippe Giral
- Service d'Endocrinologie-Métabolisme, AP-HP, Hôpital de la Pitié, Paris, France
| | - Ronan Roussel
- Département d'Endocrinologie, Diabétologie et Nutrition, DHU FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France; INSERM U1138, Centre de Recherche des Cordeliers, Paris, France; Université Paris-Diderot, Paris 7, Paris, France
| | - Michel Marre
- Département d'Endocrinologie, Diabétologie et Nutrition, DHU FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France; INSERM U1138, Centre de Recherche des Cordeliers, Paris, France; Université Paris-Diderot, Paris 7, Paris, France
| | - Kamel Mohammedi
- Département d'Endocrinologie, Diabétologie et Nutrition, DHU FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France; INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
| | - Eric Bruckert
- Service d'Endocrinologie-Métabolisme, AP-HP, Hôpital de la Pitié, Paris, France
| | - Martin John Chapman
- INSERM UMRS 1166 ICAN, Université Pierre et Marie Curie Paris 6, Hôpital de la Pitie, Paris, France
| | - Anatol Kontush
- INSERM UMRS 1166 ICAN, Université Pierre et Marie Curie Paris 6, Hôpital de la Pitie, Paris, France
| |
Collapse
|
20
|
Abstract
Recent studies indicate that dietary interventions have the potential to prevent and even treat cardiovascular disease, which is the leading cause of death. Many of these studies have focused on various animal models that are able to recreate one or more conditions or elevate risk factors that characterize the disease. Here, we highlight macronutrient-focused interventions in both mammalian model organisms and humans with emphasis on some of the most relevant and well-established diets known to be associated with cardiovascular disease prevention and treatment. We also discuss more recent dietary interventions in rodents, monkeys, and humans, which affect atherosclerosis and cardiovascular diseases with focus on those that also delay aging.
Collapse
|
21
|
Serum CETP concentration is not associated with measures of body fat: The NEO study. Atherosclerosis 2016; 246:267-73. [DOI: 10.1016/j.atherosclerosis.2016.01.031] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Revised: 01/18/2016] [Accepted: 01/18/2016] [Indexed: 01/22/2023]
|
22
|
Wang Y, van der Tuin S, Tjeerdema N, van Dam AD, Rensen SS, Hendrikx T, Berbée JFP, Atanasovska B, Fu J, Hoekstra M, Bekkering S, Riksen NP, Buurman WA, Greve JW, Hofker MH, Shiri-Sverdlov R, Meijer OC, Smit JWA, Havekes LM, van Dijk KW, Rensen PCN. Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. Hepatology 2015; 62:1710-22. [PMID: 26174697 DOI: 10.1002/hep.27985] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Accepted: 07/10/2015] [Indexed: 02/06/2023]
Abstract
UNLABELLED The role of Kupffer cells (KCs) in the pathophysiology of the liver has been firmly established. Nevertheless, KCs have been underexplored as a target for diagnosis and treatment of liver diseases owing to the lack of noninvasive diagnostic tests. We addressed the hypothesis that cholesteryl ester transfer protein (CETP) is mainly derived from KCs and may predict KC content. Microarray analysis of liver and adipose tissue biopsies, obtained from 93 obese subjects who underwent elective bariatric surgery, showed that expression of CETP is markedly higher in liver than adipose tissue. Hepatic expression of CETP correlated strongly with that of KC markers, and CETP messenger RNA and protein colocalized specifically with KCs in human liver sections. Hepatic KC content as well as hepatic CETP expression correlated strongly with plasma CETP concentration. Mechanistic and intervention studies on the role of KCs in determining the plasma CETP concentration were performed in a transgenic (Tg) mouse model expressing human CETP. Selective elimination of KCs from the liver in CETP Tg mice virtually abolished hepatic CETP expression and largely reduced plasma CETP concentration, consequently improving the lipoprotein profile. Conversely, augmentation of KCs after Bacille-Calemette-Guérin vaccination largely increased hepatic CETP expression and plasma CETP. Also, lipid-lowering drugs fenofibrate and niacin reduced liver KC content, accompanied by reduced plasma CETP concentration. CONCLUSIONS Plasma CETP is predominantly derived from KCs, and plasma CETP level predicts hepatic KC content in humans.
Collapse
Affiliation(s)
- Yanan Wang
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Sam van der Tuin
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
| | - Nathanja Tjeerdema
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
| | - Andrea D van Dam
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Sander S Rensen
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Tim Hendrikx
- Department of Molecular Genetics, Maastricht University, Maastricht, The Netherlands
| | - Jimmy F P Berbée
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Biljana Atanasovska
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Jingyuan Fu
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Menno Hoekstra
- Department of Biopharmaceutics, Leiden Academic Center for Drug Research, Leiden, The Netherlands
| | - Siroon Bekkering
- Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The, Netherlands
| | - Niels P Riksen
- Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The, Netherlands
| | - Wim A Buurman
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Jan Willem Greve
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Marten H Hofker
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Ronit Shiri-Sverdlov
- Department of Molecular Genetics, Maastricht University, Maastricht, The Netherlands
| | - Onno C Meijer
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Johannes W A Smit
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The, Netherlands
| | - Louis M Havekes
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Ko Willems van Dijk
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Patrick C N Rensen
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
23
|
Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers. PLoS One 2014; 9:e112835. [PMID: 25415563 PMCID: PMC4240577 DOI: 10.1371/journal.pone.0112835] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2013] [Accepted: 09/26/2014] [Indexed: 01/20/2023] Open
Abstract
Very low calorie diets (VLCD) with and without exercise programs lead to major metabolic improvements in obese type 2 diabetes patients. The mechanisms underlying these improvements have so far not been elucidated fully. To further investigate the mechanisms of a VLCD with or without exercise and to uncover possible biomarkers associated with these interventions, blood samples were collected from 27 obese type 2 diabetes patients before and after a 16-week VLCD (Modifast ∼450 kcal/day). Thirteen of these patients followed an exercise program in addition to the VCLD. Plasma was obtained from 27 lean and 27 obese controls as well. Proteomic analysis was performed using mass spectrometry (MS) and targeted multiple reaction monitoring (MRM) and a large scale isobaric tags for relative and absolute quantitation (iTRAQ) approach. After the 16-week VLCD, there was a significant decrease in body weight and HbA1c in all patients, without differences between the two intervention groups. Targeted MRM analysis revealed differences in several proteins, which could be divided in diabetes-associated (fibrinogen, transthyretin), obesity-associated (complement C3), and diet-associated markers (apolipoproteins, especially apolipoprotein A-IV). To further investigate the effects of exercise, large scale iTRAQ analysis was performed. However, no proteins were found showing an exercise effect. Thus, in this study, specific proteins were found to be differentially expressed in type 2 diabetes patients versus controls and before and after a VLCD. These proteins are potential disease state and intervention specific biomarkers. Trial Registration Controlled-Trials.com ISRCTN76920690
Collapse
|
24
|
Onat A, Altuğ Çakmak H, Can G, Yüksel M, Köroğlu B, Yüksel H. Serum total and high-density lipoprotein phospholipids: Independent predictive value for cardiometabolic risk. Clin Nutr 2014; 33:815-22. [DOI: 10.1016/j.clnu.2013.10.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Revised: 09/19/2013] [Accepted: 10/27/2013] [Indexed: 01/05/2023]
|
25
|
Vasudevan M, Tchoua U, Gillard BK, Jones PH, Ballantyne CM, Pownall HJ. Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol 2013; 7:661-70. [PMID: 24314365 PMCID: PMC4108339 DOI: 10.1016/j.jacl.2013.05.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 05/15/2013] [Accepted: 05/20/2013] [Indexed: 11/15/2022]
Abstract
BACKGROUND Obesity-linked metabolic syndrome (MetS) is associated with a dyslipidemic profile that includes hypertriglyceridemia and low plasma high-density lipoprotein (HDL) cholesterol. HDL initiates reverse cholesterol transport via macrophage cholesterol efflux (MCE). Some hypothesize that dyslipidemic patients have impaired reverse cholesterol transport. MCE to patient plasma, a metric of HDL function, inversely correlates with atherosclerotic burden. Paradoxically, MCE to plasma of hypertriglyceridemic subjects is higher than that to normolipidemic (NL) plasma. OBJECTIVE Although weight loss reduces dyslipidemia, its effect on MCE to the plasma of obese patients with MetS is unknown. Thus, we tested the hypothesis that reducing dyslipidemia with weight loss reduces the MCE capacity of MetS plasma to that of NL plasma. METHODS Cholesterol efflux (MCE) from THP-1 macrophages to plasma from NL controls and to obese patients with MetS before and after weight loss was measured. RESULTS MCE to plasma of obese patients with MetS was higher than that of control plasma (P = .006). Weight loss in patients with MetS (mean, -9.77 kg) reduced dyslipidemia, insulin resistance, and systolic blood pressure. HDL cholesterol was unchanged, and apolipoprotein A-I decreased with weight loss. Weight loss in patients with MetS normalized MCE (P < .001) to that of NL subjects. MCE correlated with apolipoprotein B levels (r² = 0.13-0.38). Chromatography showed that macrophage cholesterol initially associates with HDL but accumulates in apolipoprotein B-containing lipoproteins at later times. CONCLUSIONS Although the initial acceptor of MCE is HDL, the elevated apolipoprotein B lipoproteins are a cholesterol sink that increases MCE in patients with MetS. Weight loss results in decreased apolipoprotein B lipoproteins and decreased MCE to plasma of patients with MetS.
Collapse
Affiliation(s)
- Madhuri Vasudevan
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| | - Urbain Tchoua
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| | - Baiba K. Gillard
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| | - Peter H. Jones
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
- The Methodist Hospital DeBakey Heart and Vascular Center, 6565 Fannin St., Houston TX 77030
| | - Christie M. Ballantyne
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
- The Methodist Hospital DeBakey Heart and Vascular Center, 6565 Fannin St., Houston TX 77030
| | - Henry J. Pownall
- Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030
| |
Collapse
|
26
|
Yamamoto-Honda R, Ehara H, Kitazato H, Takahashi Y, Kawazu S, Akanuma Y, Noda M. The long-term coronary heart disease risk of previously obese patients with type 2 diabetes mellitus. BMC Endocr Disord 2013; 13:38. [PMID: 24090279 PMCID: PMC3816169 DOI: 10.1186/1472-6823-13-38] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Accepted: 09/19/2013] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Obesity is associated with insulin resistance, development of diabetes, and coronary heart disease. There is limited information on the contribution of previous obesity on the risk of coronary heart disease. We aimed to examine the effect of previous history of obesity on the occurrence of coronary heart disease in patients with diabetes. METHODS We carried out a retrospective chart analysis of 315 type 2 diabetic patients without obesity and without atherosclerotic cardiovascular events at their initial hospital visit (men/women 236/79; mean ± standard deviation; age 53.1 ± 6.6 years; maximal body mass index before enrollment (MAXBMI) 26.6 ± 3.4 kg/m2; decrease of the BMI at enrollment from MAXBMI (deltaBMI) 4.23 ± 2.62 kg/m2) to investigate the association of previous obesity (MAXBMI larger than 30 kg/m2) with the long-term incidence of cardiovascular events. Of 315 patients, forty-eight were previously obese. RESULTS After median follow-up of 13.9 years, 48 patients developed coronary heart disease. The Kaplan-Meier analysis exhibited that coronary heart disease occurred more frequently in previously obese patients than in subjects in the reference category (22 kg/m2 < or = MAXBMI < 25 kg/m2) and that the effect lasted proportionally over follow-up periods. Multivariate Cox regression models showed that hazard ratios and corresponding 95% confidence intervals of coronary heart disease for patients with previous obesity compared with subjects in the reference category were 2.52 and 1.15 to 5.50 (p value = 0.020) after adjustment for age, sex, smoking status, systolic blood pressure, total cholesterol and HDL cholesterol. In this cohort, deltaBMI strongly correlated with MAXBMI and also behaved as a risk factor. The hazard ratios and 95% confidence intervals by the increment of one standard deviation of deltaBMI after adjustment for age, sex, smoking status, systolic blood pressure, total cholesterol and HDL cholesterol were 1.38 and 1.08 to 1.79 (p value = 0.013). CONCLUSIONS Previous obesity and/or large body weight loss before admission might act as an increased risk for coronary heart disease.
Collapse
Affiliation(s)
- Ritsuko Yamamoto-Honda
- Department of Diabetes and Metabolic Medicine and Diabetes Research Center, National Center for Global Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
| | - Hideki Ehara
- The Institute for Adult Diseases, Asahi Life Foundation, 2-2-6, Nihonbashibakurouchou, Chuou-ku, Tokyo 103-0002, Japan
- Ehara Medical Clinic, 1-10 Shouwa-cho, Tuyama-city, Okayama 708-0886, Japan
| | - Hiroji Kitazato
- The Institute for Adult Diseases, Asahi Life Foundation, 2-2-6, Nihonbashibakurouchou, Chuou-ku, Tokyo 103-0002, Japan
- Department of Diabetes and Endocrinology, Oomori Red Cross Hospital, 4-30-11 Chuo, Oota-ku, Tokyo 143-8527, Japan
| | - Yoshihiko Takahashi
- Department of Diabetes and Metabolic Medicine and Diabetes Research Center, National Center for Global Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
- Division of Diabetes and Metabolism, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan
| | - Shoji Kawazu
- The Institute for Adult Diseases, Asahi Life Foundation, 2-2-6, Nihonbashibakurouchou, Chuou-ku, Tokyo 103-0002, Japan
| | - Yasuo Akanuma
- The Institute for Adult Diseases, Asahi Life Foundation, 2-2-6, Nihonbashibakurouchou, Chuou-ku, Tokyo 103-0002, Japan
| | - Mitsuhiko Noda
- Department of Diabetes and Metabolic Medicine and Diabetes Research Center, National Center for Global Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
| |
Collapse
|
27
|
Widya RL, Hammer S, Boon MR, van der Meer RW, Smit JWA, de Roos A, Rensen PCN, Lamb HJ. Effects of short-term nutritional interventions on right ventricular function in healthy men. PLoS One 2013; 8:e76406. [PMID: 24086738 PMCID: PMC3781057 DOI: 10.1371/journal.pone.0076406] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Accepted: 08/26/2013] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND A physiological model of increased plasma nonesterified fatty acid (NEFA) levels result in myocardial triglyceride (TG) accumulation, which is related to cardiac dysfunction. A pathophysiological model of increased plasma NEFA levels result in hepatic steatosis, which has been linked to abnormal myocardial energy metabolism. Hepatic steatosis is accompanied by hepatic inflammation, reflected by plasma cholesteryl ester transfer protein (CETP) levels. The current study aimed to investigate effects of these models via different nutritional interventions on right ventricular (RV) function. METHODS Fifteen men (age 25.0±6.6 years) were included and underwent magnetic resonance imaging and spectroscopy in this prospective crossover intervention study. RV function, myocardial and hepatic TG content, and CETP levels were assessed on three occasions: after normal diet, very low-calorie diet (VLCD, physiological model) and high-fat high-energy (HFHE, pathophysiological model) diet (all 3-days diets, randomly ordered, washout phase at least 14 days). RESULTS VLCD induced a decrease in mean E deceleration by 27%. Myocardial TG content increased by 55%, whereas hepatic TG content decreased by 32%. Plasma CETP levels decreased by 14% (all P<0.05). HFHE diet induced a decrease in E/A by 19% (P<0.05). Myocardial TG content did not change, whereas hepatic TG content increased by 112% (P<0.01). Plasma CETP levels increased by 14% (P<0.05). CONCLUSIONS These findings show that RV diastolic function is impaired after short-term VLCD and HFHE diet in healthy men, respectively a physiological and a pathophysiological model of increased plasma NEFA levels. After short-term VLCD, myocardial lipotoxicity may be of importance in decreased RV diastolic function. RV diastolic dysfunction is accompanied by increased hepatic TG content and plasma CETP levels after short-term HFHE diet, suggesting that systemic inflammation reflecting local macrophage infiltration in the heart may be involved in RV dysfunction.
Collapse
Affiliation(s)
- Ralph L. Widya
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, the Netherlands
- * E-mail:
| | - Sebastiaan Hammer
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Mariëtte R. Boon
- Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, the Netherlands
| | | | - Johannes W. A. Smit
- Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, the Netherlands
| | - Albert de Roos
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Patrick C. N. Rensen
- Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, the Netherlands
| | - Hildo J. Lamb
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|
28
|
Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013; 5:1218-40. [PMID: 23584084 PMCID: PMC3705344 DOI: 10.3390/nu5041218] [Citation(s) in RCA: 887] [Impact Index Per Article: 80.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Revised: 02/14/2013] [Accepted: 03/27/2013] [Indexed: 12/13/2022] Open
Abstract
Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and both medical and economical costs are expected to increase as well. The majority of these complications are related to co-morbid conditions that include coronary artery disease, hypertension, type 2 diabetes mellitus, respiratory disorders and dyslipidemia. Obesity increases cardiovascular risk through risk factors such as increased fasting plasma triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose and insulin levels and high blood pressure. Novel lipid dependent, metabolic risk factors associated to obesity are the presence of the small dense LDL phenotype, postprandial hyperlipidemia with accumulation of atherogenic remnants and hepatic overproduction of apoB containing lipoproteins. All these lipid abnormalities are typical features of the metabolic syndrome and may be associated to a pro-inflammatory gradient which in part may originate in the adipose tissue itself and directly affect the endothelium. An important link between obesity, the metabolic syndrome and dyslipidemia, seems to be the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin. The current review will focus on these aspects of lipid metabolism in obesity and potential interventions to treat the obesity related dyslipidemia.
Collapse
Affiliation(s)
- Boudewijn Klop
- Department of Internal Medicine, Diabetes and Vascular Centre, Sint Franciscus Gasthuis, Rotterdam, P.O. Box 10900, 3004 BA, The Netherlands.
| | | | | |
Collapse
|
29
|
Villard EF, El Khoury P, Duchene E, Bonnefont-Rousselot D, Clement K, Bruckert E, Bittar R, Le Goff W, Guerin M. Elevated CETP Activity Improves Plasma Cholesterol Efflux Capacity From Human Macrophages in Women. Arterioscler Thromb Vasc Biol 2012; 32:2341-9. [DOI: 10.1161/atvbaha.112.252841] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
We aim to identify the impact of endogenous cholesteryl ester transfer protein (CETP) activity on plasma capacity to mediate free cholesterol efflux from human macrophages.
Methods and Results—
Endogenous plasma CETP activity was measured in a population of 348 women. We defined a low CETP group corresponding to subjects displaying an endogenous plasma CETP activity within the first tertile and a high CETP group corresponding to subjects with an endogenous plasma CETP activity within the third tertile. Subjects from the high CETP activity group displayed a significant increase in the capacity of their plasma (+8.2%;
P
=0.001) to mediate cholesterol efflux from human acute monocytic leukemia cell line human macrophages and from ATP-binding cassette transporter A1-dependent pathway (+23.4%;
P
=0.0001) as compared with those from the low CETP activity group. Multivariate analyses revealed that the impact of CETP activity was independent of plasma lipids levels. Pre–β1-high-density lipoprotein concentrations were significantly elevated (+29.6%;
P
=0.01) in the high CETP activity group as compared with the low CETP activity group. A positive correlation between pre–β1-high-density lipoprotein levels and plasma efflux efficiency from human acute monocytic leukemia cell line human macrophages was observed (
r
=0.29,
P
=0.02).
Conclusion—
CETP leading to the improvement of plasma efflux capacity, as a result of efficient pre–β-high-density lipoprotein formation and ATP-binding cassette transporter A1 efflux, should be preserved to prevent lipid accumulation in human macrophages.
Collapse
Affiliation(s)
- Elise F. Villard
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Petra El Khoury
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Emilie Duchene
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Dominique Bonnefont-Rousselot
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Karine Clement
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Eric Bruckert
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Randa Bittar
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Wilfried Le Goff
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| | - Maryse Guerin
- From the INSERM UMRS939, Hôpital de la Pitié, Paris, France (E.F.V., P.E.K., E.B., R.B., W.L.G., M.G.); Université Pierre et Marie Curie–Paris 6, Paris, France (E.F.V., P.E.K., K.C., E.B., R.B., W.L.G., M.G.); Institute of Cardiometabolism and Nutrition, ICAN Paris, France (E.F.V, P.E.K., E.D., D.B.-R., K.C., E.B., R.B., W.L.G., M.G.); Department of Endocrinology (E.D., E.B.), and Department of Metabolic Biochemistry (D.B.-R., R.B.), Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié, Paris,
| |
Collapse
|
30
|
Bibliography. Hyperlipidaemia and cardiovascular disease. Current world literature. Curr Opin Lipidol 2012; 23:386-91. [PMID: 22801387 DOI: 10.1097/mol.0b013e32835670af] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|